CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Core Insights - Cumberland Pharmaceuticals reported a 31% increase in fourth quarter 2025 net revenues, totaling $13.7 million, compared to the same period last year [1] - For the full year 2025, net revenues reached $44.5 million, an 18% increase year-over-year, achieving the company's goal of double-digit revenue growth [1] - The company ended 2025 with total assets of $76.8 million, liabilities of $52.3 million, and shareholders' equity of $24.9 million [1] Financial Performance - The net loss for 2025 was $2.9 million, an improvement of $3.6 million from the previous year [1] - Adjusted earnings for the year were $1.7 million, reflecting a $2.7 million improvement over 2024 [1] - Cash flow from operations was $4.9 million in 2025, representing a $5.5 million increase compared to 2024 [1] International Expansion - In February 2025, Cumberland's Vibativ® received approval in China, with SciClone Pharmaceuticals granted exclusive rights for registration and distribution [1] - The launch of Vibativ in Saudi Arabia occurred in September 2025, following an agreement with Tabuk Pharmaceutical Manufacturing Company [1] - In October 2025, Cumberland's ibuprofen injection product received regulatory approval in Mexico, with PiSA Farmaceutica obtaining exclusive distribution rights [1] Expanded Commercial Portfolio - Cumberland announced a co-commercialization agreement with RedHill Biopharma Ltd. for Talicia®, an FDA-approved treatment for H. pylori infection [1] - Talicia is now recommended as a first-line therapy in the American College of Gastroenterology clinical guidelines and is patent protected until 2042 [1] Reimbursement Milestones - Caldolor® received a permanent J-code (J1741) in December 2025, facilitating a defined reimbursement pathway for healthcare providers [1] - This milestone supports the adoption of Caldolor as a non-opioid option for pain management, enhancing access for patients [1] Clinical Developments - Cumberland announced positive top-line results from the FIGHT DMD clinical trial for ifetroban, a treatment for Duchenne muscular dystrophy heart disease [1] - The trial showed significant improvements in left ventricular ejection fractions (LVEF) for patients treated with high-dose ifetroban compared to controls [1] - Ifetroban received Orphan Drug and Rare Pediatric Disease designations from the FDA, along with Fast Track Designation for further development [1]